-
Mashup Score: 11
IL-12 is dispensable for CD8 T cell responses to mRNA vaccination, but an Il12 mRNA-LNP enhances CD8 T cell memory and protection.
Source: www.science.orgCategories: General Medicine NewsTweet
-
Mashup Score: 30
Prosurvival tumor necrosis factor receptor (TNFR) superfamily (TNFRSF) members on T cells, including 4-1BB, CD27, GITR, and OX40, support T cell accumulation during clonal expansion, contributing to T cell memory. During viral infection, tumor necrosis factor superfamily (TNFSF) members on inflammatory monocyte-derived antigen-presenting cells (APCs) provide a postpriming signal (signal 4) for T cell accumulation, particularly in the tissues. Patients with loss-of-function mutations in TNFR/TNFSF members reveal a critical role for 4-1BB and CD27 in CD8 T cell control of Epstein-Barr virus and other childhood infections and of OX40 in CD4 T cell responses. Here, on the 20th anniversary of a previous Annual Review of Immunology article about TNFRSF signaling in T cells, we discuss the effects of endogenous TNFRSF signals in T cells upon recognition of TNFSF members on APCs; the role of TNFRSF members, including TNFR2, on regulatory T cells; and recent advances in the incorporation of TNF
Source: www.annualreviews.orgCategories: General Medicine NewsTweet
-
Mashup Score: 23ClinicalTrials.gov - 2 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine NewsTweet-
Excited to help lead Phase 2/3 frontline metastatic #melanoma TeLuRide-006 study of pembro +/- novel IV TLR7/8 agonist EIK1001. Super interesting pre-clinical & prelim responses in PD1 refractory dz. Trial is open in #Pittsburgh & globally for accrual! https://t.co/wfnUvAoKWO https://t.co/YPmxULeyL4
-
-
Mashup Score: 52ClinicalTrials.gov - 2 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine NewsTweet
-
Mashup Score: 244Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial - 2 month(s) ago
Nature Medicine – In a non-prespecified interim analysis of a phase 1 trial, autologous PRAME-directed TCR T cell therapy was safe and elicited durable responses in patients with recurrent and/or…
Source: www.nature.comCategories: General Medicine NewsTweet-
Extremely excited re: IMA203 - PRAME TCR T cells Ph 1 study published in @NatureMedicine! This is a transformative Rx in #melanoma for HLA-A201+ & PD1 refractory pts. Compared to TIL, easier to make, less toxic & so far ~2x response rate in heavily pre-Rx. https://t.co/HVgl1QRQfQ https://t.co/EPRliSoXbz
-
-
Mashup Score: 237Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial - 3 month(s) ago
Nature Medicine – In a non-prespecified interim analysis of a phase 1 trial, autologous PRAME-directed TCR T cell therapy was safe and elicited durable responses in patients with recurrent and/or…
Source: www.nature.comCategories: General Medicine NewsTweet-
Extremely excited re: IMA203 - PRAME TCR T cells Ph 1 study published in @NatureMedicine! This is a transformative Rx in #melanoma for HLA-A201+ & PD1 refractory pts. Compared to TIL, easier to make, less toxic & so far ~2x response rate in heavily pre-Rx. https://t.co/HVgl1QRQfQ https://t.co/EPRliSoXbz
-
-
Mashup Score: 212025 Spring Scientific - 4 month(s) ago
The 2025 SITC Spring Scientific, Cellular Therapy for Solid Tumors, will address the recent advances in adoptive cellular therapy for solid tumors and rate-limiting challenges that impede bringing these novel therapies to patients in need.
Source: www.sitcancer.orgCategories: General Medicine News, Hem/OncsTweet-
I'm honored to speak & participate in this session on TCR cancer therapeutics @sitcancer Spring Scientific - March 12–14 in San Diego. The agenda for this meeting looks absolutely FAB-U-LOUS. Anybody interest in solid tumor cell therapy should be there. https://t.co/jIqNR0Cgm2 https://t.co/xLGXCnUaKt
-
-
Mashup Score: 20Dr. Jason Luke's Journey in Immuno-Oncology Innovation | OncoDaily - 6 month(s) ago
In this episode of OncoDaily, Dr. Jason J. Luke, a leading expert in Malignant Hematology and Medical Oncology, Associate Director for Clinical Research at H…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
Appreciated interview w @oncodaily to discuss trends in cancer #immunotherapy, my work, as well as role of professional societies & mentorship in career development. Focus on something you are passionate about, find great mentors & GRIND! Happy holidays! https://t.co/T3ArQe9n8K https://t.co/jZC9A0Udqc
-
-
Mashup Score: 202023 Targets for Cancer IO: A Deep Dive Series - 7 month(s) ago
The Society for Immunotherapy of Cancer (SITC) is pleased to offer a second highly anticipated series of six live webinars to address key questions in the field of cancer immunotherapy, both in-depth and in an easily accessible format.
Source: sitcancer.orgCategories: General Medicine News, Hem/OncsTweet-
Looking forward to moderating this @sitcancer Deep Dive into Co-stim along w @merghout featuring 3 tremendous talks from rising stars in the field covering novel strategies, ICI combos & CART @hamieh @juanosoriomd & @RZappasodi. Plz register & join us! https://t.co/Jw5BLyIdJb https://t.co/PeJRsTEiAK
-
-
Mashup Score: 1Next-generation combination approaches for immune checkpoint therapy - 7 month(s) ago
Nature Immunology – In this Review, Sharma and colleagues describe the current landscape of combination therapies and discuss requirements for the development of effective combination strategies.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
RT @KingOfPathogens: For the immunologists still on X https://t.co/FPGlnxBDRs